T2397

Topiroxostat (FYX-051) is a selective xanthine oxidase inhibitor developed for the treatment and management of hyperuricemia and gout.

DDD100097 is a potent N-myristoyltransferase inhibitor with potential inhibitory effects on Trypanosoma brucei, which can be used to study neurological disorders.

DDD-028 is a potential non-opioid and non-cannabinoid analgesic. It was used for treating neuropathic and inflammatory pain.

DDRI-18 is a novel small molecule inhibitor that regulates the DNA damage response with sensitizing and anticancer activities, inhibits non-homologous end-joining (NHEJ) DNA repair and enhances the cytotoxicity of anticancer DNA damage compounds.

Deacylcortivazol (DAC) is a potent glucocorticoid. When incubated with glucocorticoid-resistant mutants derived from the glucocorticoid-sensitive human leukemic cell line CEM-C7, DAC caused significant growth inhibition. The cytotoxicity of DAC at concent

Deltasonamide is a potent and selective inhibitor of PDE6δ‐KRas.

Deltazinone is a selective PDEδ inhibitor. Deltazinone exhibits less unspecific cytotoxicity and demonstrates a high correlation with the phenotypic effect of PDEδ knockdown in a set of human pancreatic cancer cell lines.

Deox B 7,4 is a reversible microtubule inhibitor that acts by increasing lysosomal V-ATPase activity and lysosome acidity.

Topiroxostat-D4 is a deuterated compound of Topiroxostat. Topiroxostat (T2397) has a CAS number of 577778-58-6. Topiroxostat (T2397) is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout.